With eyes on first allogeneic CAR-T approval, Precision touts 100% response in 'small niche' population

Kyle LaHucik

Senior Reporter

Precision BioSciences has grand regulatory ambitions for its lead program: first allogeneic CAR-T therapy on the market, but the biotech will have to shore up …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With eyes on first allogeneic CAR-T approval, Precision touts 100% response in 'small niche' population

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

With eyes on first al­lo­gene­ic CAR-T ap­proval, Pre­ci­sion touts 100% re­sponse in 's­mall niche' pop­u­la­tion

Senior Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

With eyes on first allogeneic CAR-T approval, Precision touts 100% response in 'small niche' population